Cargando…
Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study
BACKGROUND: Ovaleap® (follitropin alfa), a recombinant human follicle-stimulating hormone intended for use in controlled ovarian stimulation in women undergoing assisted reproductive technologies (ART), showed therapeutic equivalence to Gonal-f® in a multinational, multicenter, randomized, controlle...
Autores principales: | Strowitzki, Thomas, Kuczynski, Waldemar, Mueller, Arnd, Bias, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902897/ https://www.ncbi.nlm.nih.gov/pubmed/27287439 http://dx.doi.org/10.1186/s12958-016-0164-y |
Ejemplares similares
-
Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)
por: Strowitzki, Thomas, et al.
Publicado: (2016) -
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap(®) (XM17), Comparability with Gonal-f(®), and Performance/Consistency
por: Winstel, Rainer, et al.
Publicado: (2017) -
Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”
por: Strowitzki, Thomas, et al.
Publicado: (2016) -
Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
por: Kaplan, Sigal, et al.
Publicado: (2021) -
Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f(®) in healthy women after follicle-stimulating hormone downregulation
por: Lammerich, Andreas, et al.
Publicado: (2015)